Low prevalence of anti-centromere antibodies in scleroderma in Morocco (about 272 cases);Faible prévalence des anticorps anti-centromère dans la sclérodermie au Maroc (à propos de 272 cas)

Annales de Biologie Clinique

Volumn 65, Issue 3, 2007, Pages 291-297

  Admou, B ^a   Arji, N ^b   Seghrouchni, F ^b   Missoum, H ^b   El Fenniri, L ^b   Amghar, S ^b   El Aouad, R ^b  

^a University Cadi Ayyad Faculte de Medecine et de Pharmacie de Marrakech   (Morocco)

^b INSTITUT NATIONAL D HYGIÈNE   (Morocco)

Author keywords

Anti centromere; Anti nuclear antibodies; Antibodies to extractable nuclear antigens; Scleroderma

Indexed keywords

AUTOANTIBODY;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CENTROMERE; CHILD; FEMALE; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; MOROCCO; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SYSTEMIC SCLEROSIS;

ADOLESCENT; ADULT; AGED; AUTOANTIBODIES; CENTROMERE; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MIDDLE AGED; MOROCCO; RETROSPECTIVE STUDIES; SCLERODERMA, SYSTEMIC;

EID: 34249885116     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: 10.1684/abc.2007.0061     Document Type: Article

References (43)

1. Marie I, Cabane J. Étiopathogénie des sclérodermies. Les sclérodermies. Rev Prat 2002 ; 52 : 1873-81.
2. Camille F, Nakhle A, Stéphane B. Comment reconnaître une sclérodermie. Les sclérodermies. Rev Prat 2002 ; 52 : 1884-90.
3. Carwile LeRoy E. Sclérodermie systémique. In : Bennet JC, Plum F, Gill GN, et al., eds. Traité de médecine interne. Paris : Flammarion, 1997 : 1483-7.
4. Tager RE, Tikly M. Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans. Rheumatol 1999 ; 38 : 397-400.
5. Allcock RJ, Forrest I, Corris PA, Crook PR, Griffiths D. A study of de prevalence of systemic sclerosis in northeast England. Rheumatology 2004 ; 43 : 596-602.
6. Cabane J, Permal S. La sclérodermie 1994. www.http://users.win.be.
7. Mayes MD, Lacey Jr. JV, Dimmer JB, et al. Prevalence, incidence, survival and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003 ; 48 : 2246-55.
8. Farge D. Les sclérodermies : pour la pratique. Rev Prat 2002 ; 52 : 1923-5.
9. Diot E, Yalat C, Boissinot E, et al. Stratégie pour le diagnostic précoce de l'atteinte pulmonaire dans la sclérodermie systémique. Rev Mal Respir 2000 ; 17 : 1073-80.
10. Hietarinta M, Ilonen J, Lassilas O, Hietaharju A. Association of HLA antigens with anti-Scl-70-antibodies and clinical manifestations of systemic sclerosis. Br J Rheumatol 1994 ; 33 : 323-6.
11. Black C, Briggs D, Welsh K. The immunogenetic background of scleroderma-an overview. Clin Exp Dermatol 1992 ; 17 : 73-8.
12. Harris ML, Rosen A. Autoimmunity in scleroderma : the origin, pathogenetic role and clinical significance of autoantibodies. Curr Opin Rheumatol 2003 ; 15 : 778-84.
13. Sohail SA, Filemon Tan K. Identification of novel targets in scleroderma : update on population studies, cDNA arrays, SNP analysis, and mutations. Curr Opin Rheumatol 2003 ; 15 : 766-71.
14. Jun JB, Kuechle M, Harlan JM. Elkon, Keith B. Fibroblast and endothelial apoptosis in systemic sclerosis. Curr Opin Rheumatol 2003 ; 15 : 756-60.
15. Crilly A, Hamilton J, Clark CJ, Jardine A, Madhok R. Analysis of the 5′ flanking region of the interleukin 10 gene in patients with systemic sclerosis. Rheumatology 2003 ; 42 : 1295-8.
16. Boffa JJ, Rossert J. Atteintes rénales sclérodermiques. Les sclérodermies. Rev Prat 2002 ; 52 : 1910-4.
17. Mouthon L, De La Peňa-Lefebvre PG, Chanseaud Y, Tamby MC, Boissier MC, Guillevin L. Pathogénie de la sclérodermie systémique : aspects immunologiques. Ann Med Interne (Paris) 2002 ; 153 : 167-78.
18. Genth E, Mierau R. Rheumaklinik und Rheumaforschungsinstitut Aachen. Diagnostic significance of scleroderma and myositis-associated autoantibodies. Z Rheumatol 1995 ; 54 : 39-49.
19. Reimer G. Autoantibodies against nuclear, nucleolar and mitochondrial antigens in systemic sclerosis (scleroderma). Rheum Dis Clin North Am 1990 ; 16 : 169-83.
20. Meyer O. Syndrome Crest. Ann Med Interne (Paris) 2002 ; 153 : 183-8.
21. Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Antigen specificity of antihistone antibodies in localised scleroderma. Arch Dermatol 1994 ; 130 : 1273-7.
22. Yamane K, Ihn H, Kubo M, et al. Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma. Rheumatol 2001 ; 40 : 683-6.
23. Sato S, Hamaguchi Y, Hasegawa M. Takehara. K. Clinical significance of anti-topoisomerase I antibody levels determined by ELISA in systemic sclerosis. Rheumatol 2001 ; 40 : 1135-40.
24. González-Buitrago JM, González C, Hernando M, et al. Antibodies to centromere antigens measured by an automated enzyme immunoassay. Clin Chim Acta 2003 ; 28 : 135-8.
25. Hesselstrand ARS, Shen GQ, Wiik A, Åkesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatol 2003 ; 42 : 534-40.
26. Harvey GR, Butts S, Rands AL, Patel Y, McHugh NJ. Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis. Clin Exp Immunol 1999 ; 117 : 395-402.
27. Wollheim FA. Classification of systemic sclerosis. Visions and reality. Rheumatology 2005 ; 44 : 1212-6.
28. Tormey VJ, Bunn CC, Denton CP, Black CM. Anti-fibrillarin antibodies in systemic sclerosis. Rheumatology 2001 ; 40 : 1157-62.
29. Meyer O. Du syndrome de Thibierge-Weissenbach (1910) aux anticorps anti-centromère (1980). De la clinique à la biologie. Ann Med Interne (Paris) 1999 ; 150 : 47-52.
30. Huong Du Le T, Sauvaget F, Johanet C, et al. Anticorps Anti-Scl70 dans la sclérodermie systémique. Ann Dermatol Venereol 1990 ; 117 : 103-7.
31. McNeilage LJ, Youngchaiyud U, Whittingham S. Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 1989 ; 32 : 54-60.
32. Nietert PJ, Mitchell HC, Bolster MB, Shaftman SR, Tilley BC, Silver RM. Racial variation in clinical and immunological manifestations of systemic sclerosis. J Rheumatol 2006 ; 33 : 263-8.
33. Ho KT, Reveille JD. The clinical relevance of autoantibodies in scleroderma. Arthritis Res Ther 2003 ; 5 : 80-93.
34. Fabien N, Rousset H. Diagnostic immunologique des sclérodermies. Pathol Biol 2002 ; 50 : 243-55.
35. Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y. Clinical and serological heterogeneity in patients with anti-centromere antibodies. J Rheumatol 2005 ; 32 : 1488-94.
36. Virginia D, Steen MD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005 ; 35 : 35-42.
37. Takehara K, Sato S. Localised scleroderma is an autoimmune disorder. Rheumatol 2005 ; 44 : 274-9.
38. Salmon-Ehr V, Eschard C, Kalis B. Morphées : classification et prise en charge. Ann Dermatol Venereol 1998 ; 125 : 283-90.
39. Yalaoui S, Gorgi Y, Ayed K. Comparaison de trios techniques pour la recherché des anticorps anti-Scl70. Ann Biol Clin (Paris) 2001 ; 59 : 639-42.
40. Ihn H, Yamane K, Yazawa N, et al. Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis. Clin Exp Immunol 1999 ; 117 : 383-7.
41. Bizzaro N, Tozzoli R, Tonutti E, et al. Variability between methods to determine ANA, anti-dsDNA and anti-ENA autoantibodies : a collaborative study with the biomedical industry. J Immunol Methods 1998 ; 219 : 99-107.
42. Marrakchi H, Fazaa B, Gorgi Y, Jellouli A, Mokhtar I, Kamoun MR. Anticorps anti-phospholipides et sclérodermie systémique, à propos d'un cas avec revue de la littérature. Tunis Med 1995 ; 73 : 149-52.
43. Caramaschi P, Biasi D, Tonolli E, Carletto A, Bambara LM. Étude des anticorps anti-cytoplasme des polynucléaires neutrophiles (ANCA) dans la sclérodermie. Premier cas avec anti-protéinase 3 et revue de la littérature. Rev Rhum 2002 ; 69 : 265-9.